Business Wire

Blick TV Launches Switzerland’s First Digital TV Channel, Powered by Brightcove

Share

Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, today announced that Switzerland’s first 24/7 digital TV channel, Blick TV, is running on Brightcove Live™ and Video Cloud. The newly launched TV channel – which falls under media group Ringier – offers viewers both a live and video on-demand viewing experience online at Blick.ch, as well as in the Blick app for mobile devices (iOS and Android). Blick TV is a significant milestone for Ringier as the media group has invested significant resources into digital streaming including two news studios, as well as a core team of 48 reporters, editorial staff, and hosts to report on news stories daily. Blick TV brings its audiences live breaking national news stories, as well as capitalizes on its partnership with CNN to bring audiences international news stories.

As one of the largest media brands in Switzerland, reaching more than 1.5 million people daily, the Blick Group leveraged Brightcove’s video platform to adopt a mobile-first digital strategy that is capable of delivering a high-quality video experience, as well as allow its audiences to watch content on their device of choice. The launch of Blick TV highlights the importance for media companies to move towards a mobile-first, video-driven content strategy given the major shift in the way people prefer to consume content.

Using Brightcove, Blick TV live streams breaking news topics for its viewers, as well as easily creates segmented clips to store for seamless video on-demand viewing. There are also some notable features of Blick TV that highlight its competitive advantage, including:

  • Video Subtitles: Styled and positioned in the video player, an interpreter repeats the content in standard German, which is then converted to text with an opportunity to edit. Enabling smartphone use on-the-go as well as barrier-free access, subtitles are a critical component of the viewing experience and make video accessible to all audiences.
  • Portrait and Landscape Viewing: Optimized for mobile viewership, viewers are offered both portrait and landscape viewing, without the quality being compromised if it is recorded in one format and viewed in another. In portrait mode, only the central portion of the video is visible, and is the same stream resized, instead of a separate live stream. Additionally, the subtitles, Blick TV logo, and headlines are customized and positioned differently based on portrait and landscape.

“When we decided to launch Switzerland’s first digital TV station we knew how crucial a superior user experience would be,” said Thomas Spiegel, CEO, Blick Group. “With the ability to offer subtitles, as well as both portrait and landscape viewing, we are not only giving our users a premium experience, but giving ourselves a long-term competitive advantage. We attribute these breakthroughs to Brightcove’s feature-rich video platform. Since launching Blick TV, we’ve been able to increase video on-demand content, cater to all viewing preferences, and become the go-to 24/7 digital TV channel for audiences who want to view live and on-demand video content.”

“By choosing a scalable, reliable platform like Brightcove Live, Blick TV is able to achieve Ringier’s three key pillars of success: informing, entertaining, and connecting with its audiences,” said Justin Barrett, Vice President, EMEA, Brightcove. “We are thrilled that Ringier chose Brightcove to power Switzerland’s first ever digital news channel, and excited our video services are being expanded to more audiences globally.”

About Ringier

Ringier AG is an innovative, digitalized and diversified Swiss media company active in Europe, Africa and Asia. The portfolio includes over 100 subsidiaries in the areas of print, digital media, radio, ticketing, entertainment and e-commerce as well as leading digital marketplaces in the areas of automobiles, real estate and jobs. As a venture capitalist, Ringier promotes innovative digital start-ups. Founded in 1833 as a publishing house and printing house, Ringier is a family-owned company that has consistently invested in the digitalization and internationalization of the Group in recent years. In 2018, around 7300 employees in 19 countries achieved a turnover of over one billion Swiss francs. Already today, around 70 percent of the operating profit comes from the digital business, making Ringier a leading European media company. Ringier stands for pioneering spirit, independence and freedom of opinion.

About Brightcove Inc. (NASDAQ: BCOV)

We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.

Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com.

Contact information

Press Contact
Meredith Duhaime
Senior Public Relations Manager
Brightcove | 603-785-8518
mduhaime@brightcove.com
Twitter: @meredithduhaime

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 06:00:00 CESTPress release

Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin

Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 03:00:00 CESTPress release

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom